Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Established in response to the 2012 Prime Ministers Challenge on Dementia, DPUK is a multi-million pound public-private partnership, developed and led by the Medical Research Council, to accelerate progress in, and open up, dementias research.

The MRC Dementia Research Platform UK (DPUK) held its launch event on the 28th October at the Royal Society in London. 

The partnership brings together world leading researchers from universities across the UK including: Oxford, Cambridge, Edinburgh, Swansea, Newcastle, Imperial College London, University College London, Manchester and Bristol. To facilitate rapid translation there is a strong industry involvement. Six UK and international companies: Araclon, GSK, Ixico, Janssen, MedImmune and Somalogic have signed a consortium agreement which will allow shared access to the unique research resources in the DPUK, and to provide a basis for instigating joint studies.

Oxford plays a significant role in the partnership and Oxford Neuroscience researchers lead a number of projects.  This was reflected in the scientific programme of launch day.  Simon Lovestone (Psychiatry) gave a talk on the NIHR-MRC Dementia Deep and Frequent Phenotyping Feasibility Study while Richard Wade-Martins (DPAG) spoke on the UK Stem Cell Network.